Data on hyper-activation of GPVI signalling in obese patients: Towards the identification of novel antiplatelet targets in obesity
- PMID: 31372431
- PMCID: PMC6661234
- DOI: 10.1016/j.dib.2019.103784
Data on hyper-activation of GPVI signalling in obese patients: Towards the identification of novel antiplatelet targets in obesity
Abstract
This data article is associated with the manuscript "GPVI surface expression and signalling pathway activation are increased in platelets from obese patients: elucidating potential anti-atherothrombotic targets in obesity" [1]. The study refers to a combination of different approaches in order to identify platelet-derived biomarkers in obesity. A total of 34 obese patients and their lean-matched controls were included in the study. We carried out a proteomic and functional (aggregation assays) analysis to find alterations in platelet-derived signalling pathways. After that, biochemical and mechanistic (flow cytometry assays) approaches were done in order to confirm a hyperactivation of the GPVI-related signalling pathway.
References
-
- Barrachina M.N., Sueiro A.M., Izquierdo I., Hermida-Nogueira L., Guitián E., Casanueva F.F., Farndale R.W., Moroi M., Jung S.M., Pardo M., García A. GPVI surface expression and signalling pathway activation are increased in platelets from obese patients: elucidating potential anti-atherothrombotic targets in obesity. Atherosclerosis. 2019;281:62–70. - PMC - PubMed
-
- García A. Two-dimensional gel electrophoresis in platelet proteomics research, Methods. Mol. Med. 2007;139:339–353. - PubMed
-
- García A., Prabhakar S., Hughan S., Anderson T.W., Brock C.J. Differential proteome analysis of TRAP-activated platelets: involvement of DOK-2 and phosphorylation of RGS proteins. Blood. 2004;103:2088–2095. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
